# Naloxegol Health Outcome Post Authorisation Safety Study

> **NCT02813369** · — · TERMINATED · sponsor: **Kyowa Kirin Pharmaceutical Development Ltd** · enrollment: 10000 (actual)

## Conditions studied

- Opioid Induced Constipation

## Interventions

- **DRUG:** naloxegol
- **DRUG:** non-PAMORA laxative

## Key facts

- **NCT ID:** NCT02813369
- **Lead sponsor:** Kyowa Kirin Pharmaceutical Development Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2021-11
- **Final completion:** 2021-11
- **Target enrollment:** 10000 (ACTUAL)
- **Why stopped:** Not feasible to reach the required number of patient cases by the defined end of data collection milestone (Q4 2022) knowing that the study completion was planned by the end of 2023
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02813369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02813369, "Naloxegol Health Outcome Post Authorisation Safety Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02813369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*